Health systems need to use the new tools to address RSV, a leading cause of baby hospitalisations

From being a largely unknown pathogen, Respiratory Syncytial Virus (RSV) is now almost a household word – and a fearful one for families with infants and young children at risk. But new solutions, such as long-acting monoclonal antibodies (mAbs) and maternal vaccination, both recently recommended by the World Health Organization (WHO), could dramatically alter the […]
Continue reading ->
Health Policy Watch. (2024, December 8). New tools to address RSV, a leading cause of baby hospitalisations. Health Policy Watch. https://healthpolicy-watch.news/new-tools-to-address-rsv-a-leading-cause-of-baby-hospitalisations/
Related news
Julius Clinical spoke to obesity expert Professor Liesbeth van Rossum about the multi-factorial, complex and often misunderstood disease and what the future holds
15 April 2025, The NetherlandsJulius Clinical’s Scientific Officer, Associate Professor Manuel Castro Cabezas, interviewed Professor Liesbeth van Rossum, internist-endocrinologist and professor in the field of obesity at the Erasmus MC, Univ...
Recruitment milestone achieved in important Phase II study in Alzheimer’s Disease
Julius Clinical are proud to announce the successful completion of recruitment for the PRImus-AD study, a clinical Phase II study which investigates the safety and efficacy of the drug candidate PRI-002 for the treatment of Alzheimer's Disease....
Julius Clinical Strengthens its European Capabilities by Expanding Operations in Poland
Zeist, Netherlands, [February 25, 2025] – Julius Clinical, a science-driven global CRO specializing in Neurological, Cardio-Metabolic, Renal and Rare Diseases, is pleased to announce the establishment of Julius Clinical Poland, a new operational...